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Background/aim: Bloodstream infections are the major cause of morbidity, increased cost, prolonged hospitalization, and mortality
in pediatric patients. Identifying the predominant microorganisms and antimicrobial susceptibilities in centers helps to select effective
empirical antimicrobials which leads to positive clinical outcomes. We aimed to identify the causative microorganisms and their
antimicrobial susceptibilities in patients with bloodstream infections.
Materials and methods: Data belonging to patients with hematological and/or oncological diseases admitted to our hospital with fever
between January 2010 and November 2015 were analyzed.
Results: In total, 71 patients who had 111 bloodstream infection episodes were included. Responsible pathogens were detected as follows:
35.1% gram-positive microorganisms, 60.5% gram-negative bacteria, and 4.4% fungi. The most common causative gram-negative
pathogen was Escherichia coli and the most commonly isolated gram-positive microorganism was coagulase-negative staphylococci.
Conclusion: Gram-negative microorganisms were predominant pathogens in bloodstream infections. Escherichia coli and coagulasenegative staphylococci were the most commonly isolated responsible pathogens. Beta-lactam/lactamase inhibitors were suitable for
empirical treatment. However, in critical cases, colistin could have been used for empirical treatment until the culture results were
available. Routine glycopeptide use was not required. By identifying the causative microorganisms and their antimicrobial resistance
patterns, it will be possible to obtain positive clinical results.
Key words: Bloodstream infections, hematology and oncology, microorganisms

1. Introduction
Bloodstream infections (BSIs) are the main cause of
morbidity, prolonged hospitalization, increased cost,
and mortality in patients [1,2]. Underlying diseases,
applied chemotherapy protocols, central venous
catheter (CVC), radiation therapy, surgical procedures,
and mucositis may predispose patients to infections [3].
Today, more than 80% of pediatric patients receiving
cancer treatment have long-term CVCs [4]. The
majority of BSIs are related to the use of these catheters
in children.
Early diagnosis and empirical antibiotic treatment
may help improve the prognosis of BSIs. However, the
choice of empirical antibiotic treatment must be based
on the patient’s clinical status, frequently detected
isolates, and their antimicrobial susceptibility patterns
in the region [5]. In some hospitals, treatment of BSIs

caused by multiresistant bacteria is an important
problem because of increasing antibiotic resistance [6].
Until the 1990s gram-positive microorganisms were
the pathogens most often responsible for BSIs; today
gram-negative pathogens are frequently isolated in
many centers [7]. It is very important to know the local
prevalence of responsible microorganisms for appropriate
management. For this purpose, in our study we aimed to
identify the microorganisms that were isolated from blood
culture during the febrile period in pediatric hematology
and oncology patients, their antimicrobial susceptibility
patterns, and clinical outcomes.
2. Materials and methods
2.1. Study populations
This was a cross-sectional study that included febrile
patients with hematological and/or oncological diseases
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that were diagnosed as BSIs, followed between January
2010 and November 2015. Demographic and clinical
characteristics of patients were collected from the database
retrospectively. Approval for the study was obtained from
the Ethics Committee of Ankara University Faculty of
Medicine (2016/04).
2.2. Case definitions
Patients met the following criteria: (1) hematological and/or
oncological disease diagnosis, (2) fever (body temperature
≥38 C° once or ≥37.5 C° for at least 2 h, measured with an
infrared tympanic thermometer), and (3) positive blood
culture result (BSI or CRBSI). Neutropenia was defined as
an ANC <1000 cells/µL, with severe neutropenia as ANC
<500 cells/µL. If CRP level was <5 mg/L, it was accepted
as negative.
Bloodstream infection (BSI) was defined as 1 positive
blood culture with pathogenic microorganisms or ≥2
separately positive blood cultures with nonpathogenic
microorganisms of normal skin flora (CNS (coagulasenegative
staphylococci),
Streptococcus
viridans,
Propionibacterium spp., Bacillus spp.) that were not related
to an infection at another site.
Diagnosis of catheter-related bloodstream infection
(CRBSI) was based on the Infectious Disease Society of
America (IDSA) clinical and practice guidelines for the
diagnosis and management of intravascular catheter related
infections—2009 update, which contains the following
criteria: detecting the same microorganism on the catheter
and peripheral blood culture, and microorganism’s
reproduction time is detected at least 2 h earlier in catheter
blood culture than in peripheral blood culture [8]. These
pathogens were not related to an infection at another site.
Clinical signs of infection (fever, chills, and
hypotension) were detected at the same time as positive
blood culture. Asymptomatic bacteremia was not
considered an infection.
The exclusion criteria were as follows: (1) antibiotic
treatment prior to admission to the hospital, (2) absence
of simultaneous catheter and peripheral blood culture, (3)
asymptomatic patients, (4) one positive blood culture with
nonpathogenic microorganisms of normal skin flora.
2.3. Culture and identification
During the febrile period, blood samples of at least 2
mL were taken simultaneously from the peripheral
vein and both of the catheter lumens. All blood samples
were taken after the application of septic processes and
cultured with a BACTEC 9240 system (Becton Dickson,
Sparks, MD, USA). Antimicrobial susceptibility patterns
of microorganisms were detected with the Phoenix 100
ID/AST system (Becton Dickinson, Phoenix 100, MD,
USA) according to the Clinical and Laboratory Standards
Institute (CLSI) guidelines.
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2.4. Treatment
All patients with BSIs were treated with systemic
antimicrobial drugs. According to the Infectious Disease
Society of America (IDSA) guidelines, for empirical
treatment, antipseudomonal broad-spectrum betalactamase antibiotics were used if ANC <500 /mm3, or
third generation cephalosporin was used if ANC >500 /
mm3 and there were no signs of sepsis [8]. In catheterrelated bloodstream infections (CRBSIs), catheter removal
was performed under the following conditions: S. aureus,
Pseudomonas spp., and fungus related catheter infections,
nontunneled catheter infections, all tunnel infections,
complicated catheter infections, and in septic patients.
If catheter removal was not required, ALT was
used with systemic intravenous antibiotics in patients
documented with CRBSI, which includes concentrated
antibiotic solution (vancomycin 5 mg/mL, gentamicin
1 mg/mL, amikacin 5 mg/mL, ciprofloxacin 0.2 mg/mL,
ampicillin 10 mg/mL, ceftazidime 0.5 mg/mL, cefazolin 5
mg/mL), sterile normal saline, and heparin (100 U/mL).
This mixture was introduced into the catheter lumen
(usually 3 mL) and then the catheter was locked. Antibiotic
lock solution was replaced every 24 h. The duration of ALT
was varied according to the causative microorganisms;
ALT treatment for Enteroccoccus spp. was 7–14 days, CNS
was 10–14 days, and gram-negative bacilli was 10–14
days. Control catheter and peripheral blood cultures were
performed after 72 h of treatment. Patients were followed
up according to clinical signs. If fever was persistent and
sterile blood culture could not be achieved, catheter was
removed, and catheter tip culture was performed.
In addition, only systemic antibiotics were applied
for BSIs in accordance with antimicrobial susceptibility.
Patients with gram-negative microorganisms were usually
treated for 14 days and gram-positive BSIs were commonly
treated for 10 days.
All patients were followed for at least 6 months.
2.5. Statistical analysis
SPSS version 18.0 (Chicago, IL, USA) was used for analysis
of results. Categorical variables were compared using the
chi-square test or Fisher’s exact test. Continuous variables
were compared using the t-test or Mann–Whitney U test.
A P-value was considered statistically significant if it was
detected as ≤0.05.
3. Results
Between January 2010 and November 2015, 71 pediatric
patients with 111 BSIs were retrospectively included in the
study. The median age of patients was 90 (range: 3–247)
months. Male/female ratio was 1.7/1. Common underlying
diseases were acute lymphoblastic leukemia (ALL) (33.8%),
acute myeloid leukemia (AML) (28.2%), solid organ tumors
(22.5%), aplastic anemia (4.2%), thalassemia major (4.2%),
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lymphoma (2.8%), myelodysplastic syndrome (1.4%),
hemophagocytic lymphohistiocytosis (1.4%), and chronic
myeloid leukemia (1.4%). Of 71 patients, 48 (67.6%) had 1
episode, 12 (16.9%) had 2 episodes, and 11 (15.5%) had ≥3
episodes. CRBSIs were identified in 80 (72.1%) episodes
that included 58 Hickman catheters, 18 totally implantable
ports, and 4 nontunneled central venous catheters.
Eighty-nine (80.2%) episodes occurred during the
neutropenic period; 83 (74.8%) of them had severe
neutropenia. The median value of ANC was 100 (range:
0–16,800) cell/mm3. The mean level of CRP was 86.1 ± 79.1
(median: 65.1; range: 1–389) mg/L. The median duration
of neutropenia was 10 (range: 1–525) days. Demographic
and clinical features of patients are summarized in Table 1.
For a total of 111 BSIs, gram-positive microorganisms
were responsible for 35.1%, gram-negative microorganisms
were responsible for 60.5%, and 4.4% were due to fungi.
Escherichia coli was the most commonly detected gramnegative pathogen (16.7%) and CNS was the most
commonly isolated gram-positive microorganism
(16.7%). Common responsible microorganisms detected
in CRBSIs were as follows: CNS (18.1%), E. coli (15.7%),
K. pneumoniae (13.3%), Pseudomonas spp. (12.0%), alphahemolytic Streptococcus (7.2%), Enterococcus spp. (6.0%),
Candida spp. (6.0%), Acinetobacter spp. (4.8%), and
Serratia marcescens (4.8%). However, the most commonly
identified pathogens in other BSIs were E. coli (19.6%),
CNS (12.9%), K. pneumoniae (12.9%), Enterococcus spp.
(12.9%), S. aureus (9.7%), and S. maltophilia (9.7%).

Between 2010 and 2015, gram-negative microorganisms
were more frequently causative for BSIs, though grampositive pathogens were predominant in 2011. The
distribution of causative microorganisms by year is given
in Figure. Polymicrobial etiology was detected in 3 (2.7%)
episodes. The causative microorganisms are given in Table
2.
In our study, unlike other gram-negative bacteria, K.
pneumoniae had lower beta-lactam susceptibility. Extended
spectrum beta-lactamase (ESBL) was produced by 60% of
Klebsiella spp. and 42.1% of E. coli. In addition, 15.8% of E.
coli and 26.7% of Klebsiella spp. produced carbapenemase.
Colistin resistance was detected for only one gram-negative
bacteria, Acinetobacter spp., and quinolone resistance of E.
coli and K. pneumoniae was detected in 75% and 55.6%,
respectively. Enterococcus spp. had 11.1% (1/9) ampicillin
sensitivity and 33.3% (3/9) vancomycin resistance.
Enterobacteriaceae had 16.2% carbapenem resistance. In
addition, methicillin-resistant Staphylococcus aureus was
not detected in our study. Antibiotic susceptibility patterns
of causative microorganisms are given in Tables 3 and 4.
All patients with BSIs were treated with intravenous
antibiotic therapy. The most commonly used antimicrobial
agents were as follows: piperacillin tazobactam,
cefoperazone sulbactam, meropenem, and ceftriaxone
against gram-negative microorganisms, and teicoplanin
and vancomycin against gram-positive pathogens. The
mean duration of treatment was 11.3 ± 5.86 days.
Of these 111 episodes, 108 were successfully treated,

Table 1. Demographic and clinical features of patients with bloodstream infections.
Characteristic

n

Patients’ underlying disease

n (%)

Total number of patients

71

Acute lymphoblastic leukemia

24 (33.8)

Age, median (range), months

90 (3–247)

Acute myeloid leukemia

20 (28.2)

Male n (%)

45 (63.4)

Solid organ tumors

16 (22.5)

Total blood culture positivity

111

Aplastic anemia

3 (4.2)

Catheter related bloodstream infections

80

Thalassemia major

3 (4.2)

Lymphoma

2 (2.8)
1 (1.4)

Catheter type
Hickman

58

Myelodysplastic syndrome

Port

18

Hemophagocytic lymphohistiocytosis 1 (1.4)

Nontunneled central venous catheter

4

Chronic myeloid leukemia

C-reactive protein levels, mg/L

86.1 ± 79.1

White blood count, cell/mm3

1907.2 ± 3471.9

Absolute neutrophil count (ANC), cell/mm3

1187.4 ± 2985.3
3

Number of episodes (ANC <1000 cell/mm )

89

Number of episodes (ANC <500 cell/mm )

83

3

1 (1.4)

Neutropenia duration (day)

23.1 ± 56.6

Mortality

3 (2.7%)
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Figure. Distribution of causative microorganisms of bloodstream infections in pediatric patients by year.

Table 2. The responsible microorganisms of bloodstream infections.

E. coli

CRBSIs
n (%)
13 (15.7)

Other BSIs Total number
n (%)
n (%)
6 (19.6)
19 (16.7)

CNS

15 (18.1)

4 (12.9)

19 (16.7)

K. pneumoniae

11 (13.3)

4 (12.9)

15 (13.2)

Pseudomonas spp.

10 (12.0)

2 (6.5)

12 (10.5)

Enterococcus spp.

5 (6.0)

4 (12.9)

9 (7.9)

Acinetobacter spp.

4 (4.8)

2 (6.5)

6 (5.3)

Alpha-hemolytic Streptococcus

6 (7.2)

0 (0)

6 (5.3)

Serratia marcescens

4 (4.8)

1 (3.2)

5 (4.4)

S. aureus

2 (2.4)

3 (9.7)

5 (4.4)

Candida spp.

5 (6.0)

0 (0)

5 (4.4)

S. maltophilia

1 (1.2)

3 (9.7)

4 (3.5)

Enterobacter spp.

3 (3.6)

0 (0)

3 (2.6)

A. xylosoxidans

2 (2.4)

1 (3.2)

3 (2.6)

Orchobactrum anthropi

0 (0)

1 (3.2)

1 (0.9)

Leuconostoc spp.

1 (1.2)

0 (0)

1 (0.9)

Campylobacter jejuni

1 (1.2)

0 (0)

1 (0.9)

Total number

83 (100)

31 (100)

114 (100)

CNS: coagulase-negative staphylococci

but 7-day mortality occurred in 2.7% of episodes due to
septicemia. Microorganisms that were responsible for
mortality were as follows: E. coli (n = 1), K. pneumonia (n =
1), and Serratia marcescens (n = 1). The mean CRP level was
84.95 ± 79.69 (median, 63; range, 1–389) in the mortality
group and 153.33 ± 54.90 (median, 161; range, 95–204)
in surviving patients. Although there were no significant
differences in white blood cells count, neutrophil count,
duration of neutropenia, and catheterization duration, the
CRP levels were significantly higher in the episodes that
concluded with 7-days mortality (P < 0.001).
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4. Discussion
Children with hematological and/or oncological disease
have a high risk for infections due to neutropenia,
immunosuppressive
therapy,
chemotherapy,
radiotherapy, impaired mucosal barrier, and CVC [9].
Neutropenia is the most important predisposing factor
[10]. In this study, 80.2% of episodes occurred in the
neutropenic period and 77.8% of them had severe
neutropenia. In the study by Kuo et al. neutropenia was
identified in 83.5% of BSI episodes; 73% of them had
severe neutropenia [11].
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Table 3. Gram-negative pathogens and their antibiotic susceptibility patterns (%).
n

Ceftriaxone Amikacin Gentamicin PT

CS

Meropenem Ciprofloxacin Colistin

E. coli

19

42.1

52.6

47.4

52.6 52.6 78.9

26.3

100

K. pneumoniae

15

33.3

86.7

66.7

53.3 53.3 86.7

53.3

100

Pseudomonas spp. 12

50

66.7

66.7

83.3 66.7 50

75

100

Acinetobacter spp. 6

0

33.3

33.3

50

50

60

50

100

S. marcescens

5

-

80

20

0

20

60

40

0

Enterobacter spp.

3

66.7

100

100

100

100 100

100

100

S. maltophilia

4

-

-

-

-

-

100

-

A. xylosoxidans

3

-

0

0

100

100 100

100

0

-

CS: cefoperazone/sulbactam; PT: piperacillin/tazobactam
Table 4. Gram-positive pathogens and their antibiotic susceptibility patterns (%).
n

Ampicillin SAM Teicoplanin Vancomycin Linezolid

CNS

19

0

0

100

100

100

Enterococcus faecalis

1

100

-

100

100

100

Enterococcus faecium

8

0

-

37.5

37.5

100

Alpha-hemolytic Streptococcus

6

0

-

100

100

100

S. aureus

5

0

100

-

100

100

CNS: coagulase-negative staphylococci; SAM: sulbactam ampicillin

Responsible pathogens may vary between centers
according to the use of empirical intravenous antibiotics
and the rate of compliance with antisepsis procedures.
Gram-positive microorganisms are reported as the
most commonly responsible etiologic agents in many
centers. This has been suggested as being linked to
the following reasons: (1) microorganisms may be
transmitted from colonized skin during the insertion
of CVC; (2) deterioration of mucosal integrity with
chemotherapeutic and radiotherapeutic treatment; and
(3) antibiotic prophylaxis [12,13]. Some studies suggested
that early generation quinolones may help to decrease the
frequency of gram-negative infections. However, similar
effect was not detected for gram-positive infections [14].
In the literature, gram-positive microorganisms were
detected as being predominant in BSIs [9,15]. However,
gram-negative bacteria were reported more often in
some studies [11,16,17]. They suggested that gramnegative pathogens were three times more frequent than
gram-positive organisms due to the low rate of catheter
use and not being administered quinolone prophylaxis
[16,17]. Ye et al. analyzed data belonging to children with
acute leukemia; gram-negative bacteria (53.8%), grampositive bacteria (45%), and fungi (1.2%) were isolated

in BSIs. They suggested that semipermanent catheters
that were inserted in all patients with acute leukemia
were responsible for gram-positive bacteria causing BSIs.
Therefore, they reported that the most frequently isolated
pathogen was CNS, unlike other studies [18].
In our study, all patients had long and short-term
central venous catheters. Although gram-negative
organisms were detected at significantly higher rates, CNS
(18.1%) was the most causative pathogen for CRBSIs.
Celebi et al. reported similar results in Turkey. They
analyzed data belonging to 31 pediatric hematologyoncology patients with CRBSIs. They suggested that CNS
was the most common cause of CRBSIs due to hand
contamination during catheter manipulations [19]. In
the study by Kar et al., data belonging to 68 children who
received chemotherapy for malignancy were analyzed.
Although they found that gram-negative bacteria (47.2%)
was common, Staphylococcus spp. and CNS were the most
commonly isolated pathogens in blood culture [20]. In
another study conducted in Turkey, Aslan et al. reported
that gram-positive cocci (56.4%), gram-negative bacilli
(18.9%), and fungi (12.7%) were responsible for BSIs in
children with febrile neutropenia. In addition, CNS was
the most commonly isolated pathogen [21].
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Nowadays mortality and morbidity may be reduced
with appropriate empirical antimicrobial therapy [22].
However, it is important to identify the antimicrobial
susceptibilities of the flora in every center. We found
that susceptibility of third generation cephalosporin was
66.7% for Enterobacter spp., and this rate was lower in E.
coli, Pseudomonas spp., and Klebsiella spp. (42.1%, 50%,
and 33.3%, respectively). Susceptibilities of piperacillintazobactam and cefoperazone-sulbactam were very high
among gram-negative microorganisms; therefore, these
agents are used as the first choice in our clinic.
Extended spectrum beta-lactamase-producing and
carbapenem-resistant Enterobacteriaceae may cause
difficulty in treatment. In the study by Kapoor et al., ESBLproducing microorganisms such as E. coli (4/5), Klebsiella
spp. (9/10), and Pseudomonas spp. (4/4) were isolated
from blood culture. However, E. coli and Pseudomonas
spp. did not have any carbapenem resistance and Klebsiella
spp. had 40% carbapenem resistance [23]. In a study that
investigated febrile neutropenia in children with cancer in
Turkey, ESBL production was reported as 40.0% and 20.0%
for E. coli and Klebsiella spp., respectively [24]. Thacker et
al. detected the following ESBL producing microorganisms:
E. coli (47.8%), Acinetobacter spp. (42.1%), and Klebsiella
spp. (34.8%). Carbapenem resistance was detected at the
rate of 47.8% in Klebsiella spp. and 17% in Pseudomonas
spp. They suggested that carbapenem resistance increased
more than ESBL production because of the frequent use of
carbapenems in recent years [16]. Our results were better
than in this study. We believe that our hospital had lower
carbapenemase rates due to avoidance of unnecessary use
of carbapenem.
Gram-positive pathogens are an important problem in
healthcare-associated infections. Identifying the causative
agents may be sometimes difficult due to the isolated
pathogen being a part of the normal skin flora [25].
Although different infection rates have been reported in
many studies from our country, methicillin-resistant S.
aureus is frequently isolated in many centers [21]. In a study
by Celkan et al., 50% of S. aureus had methicillin resistance
in BSIs [26]. Vancomycin resistance is another problem
in BSIs. In this study, S. aureus did not have vancomycin
resistance, but resistance was detected in Enterococcus spp.
at the rate of 33.3%. In the study by Aslan et al., S. aureus
did not have any vancomycin resistance, but resistance
was found in 40% of Enterococcus spp. infections, similar
to our findings [21]. In our hospital, antibiotic resistance
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in gram-positive microorganisms was determined to be
lower than in other studies. We believe that this is related
to the prevention of unnecessary use of glycopeptides.
Multidrug resistance of gram-negative microorganisms
can cause very severe infections and poor clinical
outcomes in immunocompromised patients [27]. In
our study, ceftriaxone susceptibility patterns of E. coli,
Klebsiella spp., and Pseudomonas spp. were 42.1%, 33.3%,
and 50%, and meropenem susceptibility patterns of these
microorganisms were 78.9%, 86.7%, and 50%, respectively.
However, all of these microorganisms were found to be
sensitive to colistin.
Kapoor et al. retrospectively evaluated 50 critically
ill children who received intravenous colistin treatment.
They detected that favorable outcome was 72%, and 14
(28%) children died due to sepsis. Although renal toxicity
occurred in five patients, they suggested that in critically
ill patients, intravenous colistin is useful for treatment of
multidrug resistance gram-negative bacterial infections
[28]. In the study by Iosifidis et al., data belonging to 13
patients with 19 episodes in which colistin was used for
infections caused by multidrug-resistant nosocomial gramnegative bacteria were analyzed. Favorable outcomes were
obtained in 16 (84.2%) patients. Two patients died due to
severe sepsis and one patient died because of underlying
disease. They found that concomitant use of colistin with
other antimicrobial drugs may result in good clinical
outcomes in most patients [29]. These results support
the findings that the use of empirical colistin should be
preferred in critically ill patients with severe clinical signs
who do not respond to standard antimicrobial therapy
because of the increasing antibiotic resistance patterns.
There are some limitations in our work. The most
important limiting factor was that the study was
retrospective. In addition, the patients may have been
admitted to another center with fever. For this reason, we
may have not included the patient in the study. However,
we believe that our work will lead to future studies
involving a larger number of patients.
In conclusion, BSIs are a serious problem in children
during the treatment of the primary disease. E. coli and CNS
were the most commonly responsible pathogens and betalactam/lactamase inhibitors were suitable for empirical
treatment. According to antimicrobial susceptibility,
sufficient time and dose of intravenous antibiotics were
applied, and clinical results were very satisfactory.
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